2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (vol 290, pg 140, 2019)

被引：1

作者：

Mach, Francois ^{[1
]}

Baigent, Colin ^{[2
]}

Catapano, Alberico L. ^{[3
]}

Koskinas, Konstantinos C. ^{[4
]}

Casula, Manuela ^{[5
,6
]}

Badimon, Lina ^{[7
]}

Chapman, M. John ^{[3
,8
,9
,13
]}

De Backer, Guy G. ^{[10
]}

Delgado, Victoria ^{[11
]}

Ference, Brian A. ^{[12
]}

Graham, Ian M. ^{[13
]}

Halliday, Alison ^{[14
]}

Landmesser, Ulf ^{[15
,16
,17
]}

Mihaylova, Borislava ^{[18
,19
,20
]}

Pedersen, Terje R. ^{[21
]}

Riccardi, Gabriele ^{[22
]}

Richter, Dimitrios J. ^{[23
]}

Sabatine, Marc S. ^{[24
,25
]}

Taskinen, Marja-Riitta ^{[26
]}

Tokgozoglu, Lale ^{[27
]}

Wiklund, Olov ^{[28
]}

Nibouche, Djamaleddine ^{[29
]}

Zelveian, Parounak H. ^{[30
]}

Siostrzonek, Peter ^{[31
]}

Najafov, Ruslan ^{[32
]}

van de Borne, Philippe ^{[33
]}

Pojskic, Belma ^{[34
]}

Postadzhiyan, Arman ^{[35
]}

Kypris, Lambros ^{[36
]}

Spinar, Jindrich ^{[37
]}

Larsen, Mogens Lytken ^{[38
]}

Eldin, Hesham Salah ^{[39
]}

Viigimaa, Margus ^{[40
]}

Strandberg, Timo E. ^{[41
]}

Ferrieres, Jean ^{[42
]}

Agladze, Rusudan ^{[43
]}

Laufs, Ulrich ^{[44
]}

Rallidis, Loukianos ^{[45
]}

Bajnok, Laszlo ^{[46
]}

Gudjonsson, Thorbjorn ^{[47
]}

Maher, Vincent ^{[48
]}

Henkin, Yaakov ^{[49
]}

Gulizia, Michele Massimo ^{[50
]}

Mussagaliyeva, Aisulu ^{[1
,51
]}

Bajraktari, Gani ^{[52
]}

Kerimkulova, Alina ^{[53
]}

Latkovskis, Gustays ^{[54
]}

Hamoui, Omar ^{[55
]}

Slapikas, Rimvydas ^{[56
]}

Visser, Laurent ^{[57
]}

机构：

[1] Geneva Univ Hosp, Dept Cardiol, 4 Gabrielle Perret Gentil, CH-1211 Geneva, Switzerland

[2] Univ Oxford, Nuffield Dept Populat Hlth, Richard Doll Bldg,Roosevelt Dr, Oxford OX3 7LF, England

[3] Univ Milan, Dept Pharmacol & Biomol Sci, Multimed IRCCS, Via Balzaretti 9, I-20133 Milan, Italy

[4] Bern Univ Hosp, Cardiol, Inselspital, Bern, Switzerland

[5] Univ Milan, Dept Pharmacol & Biomol Sci DiSFeB, Epidemiol & Prevent Pharmacol Serv SEFAP, Milan, Italy

[6] IRCCS MultiMed, Milan, Italy

[7] IR Hosp Santa Creu & St Pau, Cardiovasc Program ICCC & CiberCV, Barcelona, Spain

[8] Sorbonne Univ, Natl Inst Hlth & Med Res, INSERM, Paris, France

[9] Pitie Salpetriere Univ Hosp, Div Endocrinol Metab, Paris, France

[10] Univ Ghent, Fac Med & Hlth Sci, Publ Hlth & Primary Care, Ghent, Belgium

[11] Leiden Univ, Med Ctr, Cardiol, Leiden, Netherlands

[12] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Naturally Randomized Trials, Cambridge, England

[13] Trinity Coll Dublin, Cardiol, Dublin, Ireland

[14] Univ Oxford, Nuffield Dept Surg, NIHR Oxford Biomed Res Ctr, Oxford, England

[15] Charite Univ Med Berlin, Dept Cardiol, Berlin, Germany

[16] Berlin Inst Hlth, Berlin, Germany

[17] German Ctr Cardiovasc Res DZHK, Berlin, Germany

[18] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England

[19] Univ Oxford, NIHR Oxford Biomed Res Ctr, Oxford, England

[20] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England

[21] Oslo Univ Hosp, Prevent Cardiol, Oslo, Norway

[22] Univ Naples Federico II, Clin Med & Surg, Naples, Italy

[23] Euroclinic, Dept Cardiac, Athens, Greece

[24] Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA

[25] Harvard Med Sch, Boston, MA 02115 USA

[26] Univ Helsinki, Res Program Clin & Mol Metab, Helsinki, Finland

[27] Hacettepe Univ, Cardiol, Ankara, Turkey

[28] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Gothenburg, Sweden

[29] Algerian Soc Cardiol, Algiers, Algeria

[30] Armenian Cardiologists Assoc, Yerevan, Armenia

[31] Austrian Soc Cardiol, Vienna, Austria

[32] Azerbaijan Soc Cardiol, Baku, Azerbaijan

[33] Belgian Soc Cardiol, Ixelles, Belgium

[34] Assoc Cardiologists Bosnia & Herzegovina, Sarajevo, Bosnia & Herceg

[35] Bulgarian Soc Cardiol, Sofia, Bulgaria

[36] Cyprus Soc Cardiol, Strov Nicosia, Cyprus

[37] Czech Soc Cardiol, Brno, Czech Republic

[38] Danish Soc Cardiol, Copenhagen, Denmark

[39] Egyptian Soc Cardiol, Giza, Egypt

[40] Estonian Soc Cardiol, Tallinn, Estonia

[41] Finnish Cardiac Soc, Oulu, Finland

[42] French Soc Cardiol, Paris, France

[43] Georgian Soc Cardiol, Tbilisi, Georgia

[44] German Cardiac Soc, Mannheim, Germany

[45] Hellen Soc Cardiol, Athens, Greece

[46] Hungarian Soc Cardiol, Budapest, Hungary

[47] Iceland Soc Cardiol, Reykjavik, Iceland

[48] Irish Cardiac Soc, Dublin, Ireland

[49] Israel Heart Soc, Ramat Gan, Israel

[50] Italian Federat Cardiol, Florence, Italy

来源：

ATHEROSCLEROSIS | 2020年 / 294卷

关键词：

D O I：

10.1016/j.atherosclerosis.2019.12.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：80 / 82

页数：3

共 50 条

[41] Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI
Brandts, Julia
Bray, Sarah
Villa, Guillermo
Catapano, Alberico L.
Poulter, Neil R.
Vallejo-Vaz, Antonio J.
Ray, Kausik K.
LANCET REGIONAL HEALTH-EUROPE, 2023, 31
[42] New ESC guidelines 2019 "Diabetes, prediabetes and cardiovascular diseases" Paradigm shift in reduction of cardiovascular risk in patients with diabetes mellitus
Marx, N.
HERZ, 2019, 44 (08) : 684 - 687
[43] LIPID LOWERING THERAPY AND ATTAINMENT OF LIPID GOALS ACCORDING TO 2018 ACC/AHA AND 2019 ESC/EAS GUIDELINES ON PATIENTS WITH ASCVD ON A REAL-WORLD MEXICAN POPULATION
Vizcaino, Frida
de Los Rios Ibarra, Manuel Odin
Leiva Pons, Jose Luis
Rodriguez Reyes, Humberto
Alcocer Gamba, Marco Antonio
Cortes Lawrenz, Jorge
Lugo Gavidia, Marisol
Barragan Luna, Jaime
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1548 - 1548
[44] ATTAINMENT OF 2019 ESC/EAS LIPID TARGETS IN A COHORT OF HIGH AND VERY-HIGH RISK SUBJECTS IDENTIFIED THROUGH CARDIOLOGY AND LABORATORY DATABASES
Canovi, S.
Bonelli, E.
Foracchia, M.
Trenti, C.
Negri, E. A.
Colaiori, I.
Guiducci, V.
Calandra, S.
Bertolini, S.
Fasano, T.
ATHEROSCLEROSIS, 2021, 331 : E282 - E283
[45] RETRACTION: Interleukin-1 blockade treatment decreasing cardiovascular risk (vol 42, pg 942, 2019) (Retraction of Vol 42, Pg 942, 2019)
Zheng, Zi-Heng
CLINICAL CARDIOLOGY, 2020, 43 (04) : 410 - 410
[46] Adherence to the 2019 ESC/EAS guidelines for dyslipidaemia management in a large rheumatoid arthritis cohort: Data from the CORDIS Study Group of the Italian Society of Rheumatology
Cacciapaglia, Fabio
Spinelli, Francesca Romana
Erre, Gian Luca
Piga, Matteo
Sakellariou, Garifallia
Manfredi, Andreina
Fornaro, Marco
Viapiana, Ombretta
Perniola, Simone
Gremese, Elisa
Atzeni, Fabiola
Bartoloni, Elena
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2025, 131 : 98 - 103
[47] Mapping monocyte subsets to identify cardiovascular risk (vol 115, pg 989, 2019)
Maffei, A.
CARDIOVASCULAR RESEARCH, 2019, 115 (13) : 1885 - 1885
[48] 2019 guidelines for the diagnosis and management of chronic coronary syndromes (vol 6, pg 331, 2020)
Rosano, Giuseppe
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (03)
[49] Cardiovascular Risk Categories in Patients with Diabetes According to 2019 ESC/EASD Guidelines in Clinical Practice: Use of a Dedicated App (AWARE)
Berra, Cesare C.
Manfrini, Roberto
Ghelardi, Renata
Bollati, Paola M.
Bucciarelli, Loredana
Mirani, Marco
Muratori, Milena
Folli, Franco
DIABETES, 2021, 70
[50] IMPACT OF 2019 EAS/ESC DYSLIPIDAEMIA GUIDLINES ON MANAGEMENT OF FH PATIENTS: RECLASSIFICATION OF RISK AND LDL-C GOAL ATTAINEMENT IN THE LATVIAN REGISTRY
Gilis, D.
Nesterovics, G.
Meiere, R.
Terauda, E.
Saripo, V.
Erglis, A.
Latkovskis, G.
ATHEROSCLEROSIS, 2020, 315 : E208 - E208

← 1 2 3 4 5 →